ArticleObstetrics and gynecology international2026
Pretreatment CRP-Albumin-Lymphocyte (CALLY) Index as a Prognostic Biomarker of Survival and Recurrence-Free Survival in Patients With Early-Stage Cervical Cancer After Radical Hysterectomy: A Multicenter Retrospective Cohort Study.
Article in Obstetrics and gynecology international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction/Background: The C-reactive protein (CRP)-albumin-lymphocyte (CALLY) index is a new prognostic biomarker combining CRP, serum albumin, and lymphocyte count that can be associated with the survival of cancer patients by assessing immune, nutritional, and inflammatory status as an important immune indicator. The association of CALLY index as a marker predicting survival of cancer patients with cervical cancer (CC) remains unclear. This study aimed to evaluate the prognostic value of the CALLY index with overall survival (OS) and recurrence-free survival (RFS) in patients with early-stage CC after radical hysterectomy. Methodology: In this multicenter retrospective cohort study, we examined the medical profile of 806 women with early-stage CC who underwent Type II/III radical hysterectomy and bilateral pelvic lymphadenectomy at three centers affiliated to our center between 2012 and 2022. The CALLY index was calculated before treatment. OS and RFS were the primary endpoints. Kaplan-Meier and Cox models assessed the association between CALLY index and outcomes, adjusting for age, histology, tumor size, FIGO stage, grade, extent of lymphadenectomy, and adjuvant therapy. A CALLY index cutoff of 3 maximized discrimination (AUC 0.822; 95% CI, 0.75-0.90). Results: Five-year OS was higher with CALLY index ≥ 3 vs. < 3 (82.1% vs. 71.2%; log rank Conclusions: Pretreatment CALLY index is an independent, readily obtainable prognostic biomarker for OS and RFS after radical hysterectomy in early-stage CC. This index can be useful as a predictor of the prognosis for patients with CC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.